Adam Davis, Ph.D.

Adam Davis is Vice President of Analytical Development at Forge Biologics, leading the development of product specific and platform method development for characterization, release testing, and stability testing. He has 20+ years of experience in recombinant adeno-associated viral vector product development, process development, and manufacturing. Dr. Davis established the Forge teams dedicated to nucleic acid-based methods, protein-based methods, and cell-based methods, oversaw the qualification and transition of methods to the Quality Control team, and established a Blaze Vector Core dedicated analytic team. He previously led teams in the scalability of multiple platforms for the production, purification, and characterization of both pre-clinical and clinical recombinant gene therapy vectors at Abeona Therapeutics and BioMarin Pharmaceutical. He began his gene therapy career at Nationwide Children’s Hospital. Dr. Davis earned his Ph.D. from The Ohio State University, focusing on the rational design of recombinant AAV vector capsid for targeted delivery.